JAMA DermClinical trial
Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa.
ConclusionIn this study, among currently approved monoclonal antibody therapies for HS, adalimumab showed dominant cost-efficiency performance across multiple health systems. These findings highlight substantial international variation in biologic drug pricing and provide a framework for value-based pricing in HS therapeutics.
Pham J, Sholji T, … senior author Frew JWJAMA Dermatology